---
title: "Bristol-Myers Squibb (United States): research papers"
description: "From 2017 to 2026 (so far), authors at Bristol-Myers Squibb (United States) took part in 44 papers in the tracked journals, most of them in health economics and policy (39), statistics (3) and economics (1). It ranks #36 among the companies publishing in the tracked journals from 2023 to 2025."
url: https://scholar4ai.com/companies/bristol-myers-squibb-united-states
markdown_url: https://scholar4ai.com/companies/bristol-myers-squibb-united-states.md
license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
share_text: "From 2017 to 2026 (so far), authors at Bristol-Myers Squibb (United States) took part in 44 papers in the tracked journals, most of them in health economics and policy (39), statistics (3) and economics (1). (as of 2026-10-31)"
data_url: https://scholar4ai.com/data/rankings.json
updated: 2026-10-31T19:11:11+09:00
window: 2026-10-02 to 2026-10-31
source: OpenAlex (CC0)
---

# Bristol-Myers Squibb (United States)

Papers in the tracked journals with an author at Bristol-Myers Squibb (United States): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education.

Back to the ranking: https://scholar4ai.com/rankings/companies.md

## Key findings

- From 2017 to 2026 (so far), authors at Bristol-Myers Squibb (United States) took part in 44 papers in the tracked journals, most of them in health economics and policy (39), statistics (3) and economics (1).
- It ranks #36 among the companies publishing in the tracked journals from 2023 to 2025.
- 4 of them were published in 2025, against 3 in 2017.
- Since 2023, the institutions with the most of these papers were Bristol-Myers Squibb (United Kingdom) (12), University College London (3) and University of Sheffield (3).
- The journals publishing most of them were PharmacoEconomics - Open (13), PharmacoEconomics (5) and Metrika (1).
- The most-cited of them is “Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models” (PharmacoEconomics - Open, 2024), with 71 citations.
- Since 2023, papers in the tracked journals cited 19 of its papers 46 times; 83% of those links came from papers with a university author and 17% from its own papers.
- Its own papers since 2023 cite archived papers 56 times, 41% of them papers with a company author.

## Papers per year

*Papers per publication year and category*

| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| [Health Economics and Policy](https://scholar4ai.com/categories/health-economics-and-policy.md) | 3 | 4 | 4 | 2 | 4 | 3 | 5 | 9 | 4 | 1 |
| [Statistics](https://scholar4ai.com/categories/statistics.md) | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 |
| [Economics](https://scholar4ai.com/categories/economics.md) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [AI](https://scholar4ai.com/categories/ai.md) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| All categories | 3 | 4 | 5 | 2 | 4 | 3 | 7 | 11 | 4 | 1 |

## Where the papers come from

*Journals with the most papers, since 2023*

| # | Journal | Papers |
|---:|---|---:|
| 1 | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 13 |
| 2 | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 5 |
| 3 | [Metrika](https://scholar4ai.com/journals/metrika.md) | 1 |
| 4 | [Statistics & Probability Letters](https://scholar4ai.com/journals/statistics-probability-letters.md) | 1 |
| 5 | [Journal of Statistical Planning and Inference](https://scholar4ai.com/journals/journal-of-statistical-planning-and-inference.md) | 1 |
| 6 | [IEEE Transactions on Knowledge and Data Engineering](https://scholar4ai.com/journals/ieee-transactions-on-knowledge-and-data-engineering.md) | 1 |
| 7 | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 1 |

*Institutions with the most papers, since 2023*

| # | Institution | Papers |
|---:|---|---:|
| 1 | Bristol-Myers Squibb (United Kingdom) | 12 |
| 2 | University College London | 3 |
| 3 | University of Sheffield | 3 |
| 4 | Curtin University | 2 |
| 5 | Northwestern University | 2 |
| 6 | The University of Sydney | 2 |
| 7 | University of Illinois Chicago | 2 |
| 8 | University of Technology Sydney | 2 |
| 9 | Adelphi Group (United Kingdom) | 1 |

*Countries with the most papers, since 2023*

| # | Country | Papers |
|---:|---|---:|
| 1 | United States | 23 |
| 2 | United Kingdom | 14 |
| 3 | Australia | 2 |
| 4 | China | 2 |
| 5 | Netherlands | 2 |
| 6 | Canada | 1 |
| 7 | Switzerland | 1 |
| 8 | Denmark | 1 |
| 9 | France | 1 |
| 10 | Sweden | 1 |

*Keywords with the most papers, since 2023*

| # | Keyword | Papers |
|---:|---|---:|
| 1 | quality-adjusted life years | 6 |
| 2 | [cost-effectiveness](https://scholar4ai.com/keywords/cost-effectiveness.md) | 5 |
| 3 | health technology assessment | 4 |
| 4 | nivolumab | 4 |
| 5 | first-line therapy | 3 |
| 6 | health care costs | 3 |
| 7 | health utility | 3 |
| 8 | health-related quality of life | 3 |
| 9 | immune checkpoint inhibitors | 3 |
| 10 | [large language models](https://scholar4ai.com/keywords/large-language-models.md) | 3 |

## Most-cited papers

*Most-cited papers since 2017*

| # | Citations | Per month | Title | Journal | Published | Authors |
|---:|---:|---:|---|---|---|---|
| 1 | 71 | 2.2 | [Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models](https://doi.org/10.1007/s41669-024-00476-9) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2024-02-10 | Tim Reason, Emma Benbow, Julia Langham et al. |
| 2 | 65 | 0.6 | [Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation](https://doi.org/10.1007/s40273-017-0558-5) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2017-09-02 | Eddie Gibson, Ian Koblbauer, Najida Begum et al. |
| 3 | 61 | 0.7 | [Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes](https://doi.org/10.1007/s40273-019-00845-x) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2019-11-19 | Caitlin Smare, Khalid Lakhdari, Justin F. Doan et al. |
| 4 | 55 | 0.9 | [General population normative data for the EQ-5D-3L in the five largest European economies](https://doi.org/10.1007/s10198-021-01326-9) | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 2021-06-12 | Mathieu F. Janssen, Alan Simon Pickard, James W. Shaw |
| 5 | 41 | 1.3 | [Artificial Intelligence to Automate Health Economic Modelling: A Case Study to Evaluate the Potential Application of Large Language Models](https://doi.org/10.1007/s41669-024-00477-8) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2024-02-10 | Tim Reason, William D. Rawlinson, Julia Langham et al. |
| 6 | 30 | 0.3 | [Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment](https://doi.org/10.1007/s40273-018-0640-7) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-06-05 | Juan Marcos González, Justin F. Doan, David Gebben et al. |
| 7 | 27 | 0.3 | [An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?](https://doi.org/10.1016/j.healthpol.2018.04.008) | [Health Policy](https://scholar4ai.com/journals/health-policy.md) | 2018-04-26 | Jason T. Shafrin, Michelle Skornicki, Michelle Brauer et al. |
| 8 | 27 | 0.4 | [What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma](https://doi.org/10.1007/s40273-020-00989-1) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2021-01-11 | Sven L. Klijn, Elisabeth A. L. Fenwick, Sonja Kroep et al. |
| 9 | 25 | 0.2 | [The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature](https://doi.org/10.1007/s41669-017-0045-0) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2017-08-18 | Ashley Enstone, Mairé Greaney, Manca Povsic et al. |
| 10 | 23 | 0.3 | [Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA](https://doi.org/10.1007/s40258-019-00542-y) | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 2019-12-17 | Mustafa Oguz, Tereza Lanitis, Xiaoyan Li et al. |

## Who cites its research

*Institutions whose papers cite it most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | [Bristol-Myers Squibb (United Kingdom)](https://scholar4ai.com/companies/bristol-myers-squibb-united-kingdom.md) | Company | United Kingdom | 6 |
| 2 | University of Sheffield | University | United Kingdom | 6 |
| 3 | China Pharmaceutical University | University | China | 4 |
| 4 | Erasmus University Rotterdam | University | Netherlands | 4 |
| 5 | University of Technology Sydney | University | Australia | 3 |
| 6 | The University of Sydney | University | Australia | 3 |
| 7 | [National University of Singapore](https://scholar4ai.com/institutions/national-university-of-singapore.md) | University | Singapore | 3 |
| 8 | University College London | University | United Kingdom | 3 |
| 9 | University of York | University | United Kingdom | 3 |

## What its papers cite

*Institutions its papers cite most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | University of Sheffield | University | United Kingdom | 16 |
| 2 | Curtin University | University | Australia | 12 |
| 3 | University of Technology Sydney | University | Australia | 11 |
| 4 | The University of Sydney | University | Australia | 9 |
| 5 | Innsbruck Medical University | University | Austria | 8 |
| 6 | Universität Innsbruck | University | Austria | 8 |
| 7 | [Bristol-Myers Squibb (United Kingdom)](https://scholar4ai.com/companies/bristol-myers-squibb-united-kingdom.md) | Company | United Kingdom | 7 |
| 8 | Northwestern University | University | United States | 3 |
| 9 | Memorial Sloan Kettering Cancer Center | Healthcare | United States | 3 |

More: https://scholar4ai.com/corporate-citations.md · https://scholar4ai.com/industry-university.md

## Cite this page

Scholar4AI. (2026). Bristol-Myers Squibb (United States). Journal Research Rankings. Retrieved October 31, 2026, from https://scholar4ai.com/companies/bristol-myers-squibb-united-states

```bibtex
@misc{scholar4ai-companies-bristol-myers-squibb-united-states,
  author = {{Scholar4AI}},
  title = {Bristol-Myers Squibb (United States)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/bristol-myers-squibb-united-states}},
  urldate = {2026-10-31},
  note = {Journal Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}
```

License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).